Pietro Lampertico
Pietro Lampertico
Professore di Gastroenterologia, Università di Milano
Email verificata su unimi.it
Citata da
Citata da
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection
European Association For The Study Of The Liver
Journal of hepatology 67 (2), 370-398, 2017
EASL Clinical Practice Guidelines: management of chronic hepatitis B
European Association For The Study Of The Liver
J Hepatol 50, 227-242, 2009
Adefovir dipivoxil therapy for lamivudine‐resistant hepatitis B in pre–and post–liver transplantation patients
ER Schiff, CL Lai, S Hadziyannis, P Neuhaus, N Terrault, M Colombo, ...
Hepatology 38 (6), 1419-1427, 2003
Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos (t) ide therapy: a systematic review
GV Papatheodoridis, P Lampertico, S Manolakopoulos, A Lok
Journal of hepatology 53 (2), 348-356, 2010
Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell–mediated liver damage
C Dunn, M Brunetto, G Reynolds, T Christophides, PT Kennedy, ...
The Journal of Experimental Medicine 204 (3), 667-680, 2007
Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients
P Lampertico, M Vigano, E Manenti, M Iavarone, E Sablon, M Colombo
Gastroenterology 133 (5), 1445-1451, 2007
Adefovir rapidly suppresses hepatitis B in HBeAg‐negative patients developing genotypic resistance to lamivudine
P Lampertico, M Viganò, E Manenti, M Iavarone, G Lunghi, M Colombo
Hepatology 42 (6), 1414-1419, 2005
Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy
GV Papatheodoridis, HLY Chan, BE Hansen, HLA Janssen, P Lampertico
Journal of hepatology 62 (4), 956-967, 2015
Clinical outcome of HBeAg‐negative chronic hepatitis B in relation to virological response to lamivudine
V Di Marco, A Marzano, P Lampertico, P Andreone, T Santantonio, ...
Hepatology 40 (4), 883-891, 2004
Adefovir dipivoxil for wait‐listed and post–liver transplantation patients with lamivudine‐resistant hepatitis B: Final long‐term results
E Schiff, CL Lai, S Hadziyannis, P Neuhaus, N Terrault, M Colombo, ...
Liver Transplantation 13 (3), 349-360, 2007
Restored Function of HBV-Specific T Cells after Long-Term Effective Therapy with Nucleos (t) ide Analogues
C Boni, D Laccabue, P Lampertico, T Giuberti, M Viganò, S Schivazappa, ...
Gastroenterology Jul 14. [Epub ahead of print], 2012
Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy
P Lampertico, E Del Ninno, M Viganò, R Romeo, MF Donato, E Sablon, ...
Hepatology 37 (4), 756-763, 2003
Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian study
GB Gaeta, G Stornaiuolo, DF Precone, S Lobello, M Chiaramonte, ...
Journal of hepatology 39 (6), 1036-1041, 2003
A randomized, controlled trial of a 24‐month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum
P Lampertico, E Del Ninno, A Manzin, MF Donato, MG Rumi, G Lunghi, ...
Hepatology 26 (6), 1621-1625, 1997
Prophylaxis and treatment of hepatitis B in immunocompromised patients
A Marzano, E Angelucci, P Andreone, M Brunetto, R Bruno, P Burra, ...
Digestive and Liver Disease 39 (5), 397-408, 2007
Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus–coinfected patients
G Raimondo, MR Brunetto, P Pontisso, A Smedile, AM Maina, C Saitta, ...
Hepatology 43 (1), 100-107, 2006
PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy
G Papatheodoridis, G Dalekos, V Sypsa, C Yurdaydin, M Buti, J Goulis, ...
Journal of hepatology 64 (4), 800-806, 2016
Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients
WR Kim, T Berg, T Asselah, R Flisiak, S Fung, SC Gordon, HLA Janssen, ...
Journal of hepatology 64 (4), 773-780, 2016
Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a
V Rijckborst, BE Hansen, P Ferenci, MR Brunetto, F Tabak, Y Cakaloglu, ...
Journal of Hepatology 56 (5), 1006-11, 2012
Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B
P Fisicaro, V Barili, B Montanini, G Acerbi, M Ferracin, F Guerrieri, ...
Nature medicine 23 (3), 327-336, 2017
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20